文献速递消化系统肿瘤

DNA损伤应答通路作为结直肠癌治疗机会的综述

The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer.
PubMed 文献 · Ann Oncol · 2020-06-05

该综述聚焦结直肠癌中DNA损伤应答(DDR)通路的治疗潜力,总结了最 promising 的临床前数据及已发表的DDR抑制剂临床试验,指出疗效不佳主要源于缺乏临床和分子选择,未来研究需深入理解DDR改变以开发新策略。

要点

  • DDR通路改变是结直肠癌的潜在治疗靶点,但系统检测滞后。
  • PARP抑制剂维持治疗可能对铂类经治有效的CRC患者有益。
  • 既往DDR抑制剂试验结果不佳,主要因缺乏临床和分子选择。

核心结论

  • 未来临床前和转化研究将帮助更好地理解DDR改变在CRC中的作用,并为新策略铺平道路。

研究设计与样本

  • 综述,总结了DDR抑制剂用于CRC的已发表临床试验及临床前数据。

主要发现

  • 患者来源异种移植和类器官的功能证据提示,PARP抑制剂维持治疗可能对既往对铂类治疗有反应的CRC患者是治疗机会。
  • 已发表的DDR抑制剂用于CRC的临床试验结果令人失望,主要归因于缺乏临床和分子选择。

临床怎么用

  • 临床开发基于与其他实体瘤的类比,采用组织不可知范式。
  • 对铂类经治有效的CRC患者,可考虑PARP抑制剂维持治疗。

局限性

  • 系统性和全面的DDR改变检测在CRC中滞后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colorectal cancer (CRC) represents a major cause of cancer deaths worldwide. Although significant progress has been made by molecular and immune therapeutic approaches, prognosis of advanced stage disease is still dismal. Alterations in the DNA damage response (DDR) pathways are emerging as novel targets for treatment across different cancer types. However, even though preclinical studies have shown the potential exploitation of DDR alterations in CRC, systematic and comprehensive testing is lagging and clinical development is based on analogies with other solid tumors according to a tissue-agnostic paradigm. Recently, functional evidence from patient-derived xenografts and organoids have suggested that maintenance with PARP inhibitors might represent a therapeutic opportunity in CRC patients previously responsive to platinum-based treatment. DESIGN AND RESULTS: In this review, we highlight the most promising preclinical data and systematically summarize published clinical trials in which DDR inhibitors have been used for CRC and provide evidence that disappointing results have been mainly due to a lack of clinical and molecular selection. CONCLUSIONS: Future preclinical and translational research will help in better understanding the role of DDR alterations in CRC and pave the way to novel strategies that might have a transformative impact on treatment by identifying new therapeutic options including tailored use of standard chemotherapy.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Mauri G, Arena S, Siena S, et al. The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Ann Oncol. 2020. PMID: 32512040. doi:10.1016/j.annonc.2020.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。